Skip to main content
. Author manuscript; available in PMC: 2022 Jun 10.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1586–1594. doi: 10.1158/1078-0432.CCR-21-3874

Figure 1. Study design.

Figure 1.

Left, phase Ib: after two weeks of vismodegib lead-in, patients received vismodegib in combination with RO429097 at the indicated dose levels according to standard 3+3 design. Right, phase II: patients were randomized to receive either RO429097 alone or in combination with vismodegib at the RP2D. Green arrows indicate biopsy time points.